| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 0.68 | -0.06 (-8.24%) | 0.51 - 2.00 | 168.2 thousand (Above Avg) |
Market data as of 3:58PM 05/24/13. Quotes are delayed by at least 15 min.
| Open | 0.77 |
|---|---|
| Previous Close | 0.74 |
| Day's Range | 0.61 - 0.77 |
| Market Cap | 29.0M |
| Avg Volume (10 Day) | 66.2K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -0.34 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Neutral |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Neutral |
| Borrows within reasonable limits? | Fail |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Bacterin Receives Compliance Notice from NYSE MKT
Business Wire - Thursday 05/16/2013 9:00 AM ET
Bacterin Announces First Quarter 2013 Revenue of $8.6 Million
Business Wire - Thursday 05/09/2013 4:00 PM ET
Bacterin Announces Earnings Release and Conference Call Date for 2013 First Quarter Results
Business Wire - Tuesday 04/30/2013 8:30 AM ET
Bacterin Announces Selection of Executive Search Firm
Business Wire - Friday 04/26/2013 1:10 PM ET
| BONE | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 5.98% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 5.69 | |
| LT Debt/Equity | 5.62 | |
| Earnings Yield | -- | |
| Price/Sales | 0.86 |
| Company | Last | Change |
|---|---|---|
| Verenium Corp | 2.21 | -0.90% |
| BioSante Pharmaceuticals Inc | 1.24 | +7.83% |
| Idera Pharmaceuticals Inc | 0.68 | -2.16% |
| Aastrom Biosciences Inc | 0.55 | -1.79% |
| Hemispherx Biopharma Inc | 0.20 | -0.25% |
Data is delayed by at least 15 min.